Vasomotor symptom relief versus unwanted effects: Role of estrogen dosage

American Journal of Medicine

Volumn 118, Issue 12 SUPPL. 2, 2005, Pages 74-78

  Ettinger, Bruce ^a  

^a NONE   (United States)

Author keywords

Hormone therapy; Low dosage; Side effects; Vasomotor symptoms

Indexed keywords

CONJUGATED ESTROGEN; ESTRADIOL; ESTROGEN; ETHINYLESTRADIOL; GESTAGEN; MEDROXYPROGESTERONE; PLACEBO;

BREAST TENDERNESS; CLINICAL TRIAL; CONFERENCE PAPER; DOSE RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; ENDOMETRIUM HYPERPLASIA; FOOD AND DRUG ADMINISTRATION; HORMONAL THERAPY; HUMAN; LOW DRUG DOSE; MENOPAUSAL SYNDROME; PRIORITY JOURNAL; VAGINA BLEEDING; VASOMOTOR DISORDER;

EID: 30544450747     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2005.09.035     Document Type: Conference Paper

References (23)

1. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Labeling Guidance for Noncontraceptive Estrogen Drug Products for the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms-Prescribing Information for Health Care Providers and Patient Labeling [revision 1]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research; February 2004. Available at: http://www.fda.gov/cder/guidance/5670dft. doc. Accessed February 15, 2005.
2. American College of Obstetricians and Gynecologists Women's Health Care Physicians Executive summary hormone therapy Obstet Gynecol 104 suppl 2004 1S 4S
3. A.L. Hersh, M.L. Stefanik, R.S. Stafford National use of postmenopausal hormone therapy JAMA 291 2004 47 53
4. D.S.M. Buist, K.M. Newton, D.L. Miglioretti Hormone therapy prescribing patterns in the United States Obstet Gynecol 104 2004 1042 1050
5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Guidance for Industry: Estrogen and Estrogen/Progestin Drug Products to Treat Vasomotor Symptoms and Vulvar and Vaginal Atrophy Symptoms - Recommendations for Clinical Evaluation[draft guidance]. Rockville, MD: Division of Drug Information, Center for Drug Evaluation and Research; January 2003. Available at: http://www.fda.gov/cder/ guidance/5412dft.doc. Accessed February 15, 2005.
6. L. Speroff, R.W. Whitcomb, N.J. Kempert, R.A. Boyd, J.B. Paulissen, J.P. Rowan Efficacy and local tolerance of a low-dose, 7-day matrix estradiol transdermal system in the treatment of menopausal vasomotor symptoms Obstet Gynecol 88 1996 587 592
7. W.H. Utian, K.A. Burry, D.F. Archer Efficacy and safety of low, standard, and high dosages of an estradiol transdermal system (Esclim®) compared with placebo on vasomotor symptoms in highly symptomatic patients Am J Obstet Gynecol 181 1999 71 79
8. K. Parsey, H. Ellman, M. Rajman Transdermal Estradiol Investigators Randomized, controlled comparison of transdermal estradiol with oral conjugated estrogens for the relief of hot flushes Clin Drug Invest 20 2000 207 214
9. L. Speroff, J. Symons, N. Kempfert, J. Rowan The effect of varying low-dose combinations of norethindrone acetate and ethinyl estradiol (femHRT®) on the frequency and intensity of vasomotor symptoms Menopause 7 2000 383 390
10. M. Notelovitz, J.P. Lenihan Jr, M. McDermott, I.J. Kerber, N. Nanavati, J.-C. Arce Initial 17β-estradiol dose for treating vasomotor symptoms Obstet Gynecol 95 2000 726 731
11. M. Notelovitz, J.H. Mattox Suppression of vasomotor and vulvovaginal symptoms with continuous oral 17β-estradiol Menopause 7 2000 310 317
12. W.H. Utian, D. Shoupe, G. Bachman, J.V. Pinkerton, J.H. Pickar Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogen and medroxyprogesterone acetate Fertil Steril 75 2001 1065 1079
13. W.H. Utian, S.A. Lederman, B.M. Willimas, R.Y. Vega, W.D. Koltun, T.W. Leonard Relief of hot flushes with new plant-derived 10-component synthetic conjugated estrogens Obstet Gynecol 103 2004 245 253
14. J.F. Trabal, J.P. Lenihan, T.E. Melchione Low-dose unopposed estrogens preliminary findings on the frequency and duration of vaginal bleeding in postmenopausal women receiving esterified estrogens over a two-year period Menopause 4 1997 130 138
15. D.F. Archer, M. Dorin, V. Lewis, D.L. Schneider, J.H. Pickar Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding Fertil Steril 75 2001 1080 1086
16. M. Notelovitz, V.A. John, W.R. Good Effectiveness of Alora® estradiol matrix delivery system in improving lumbar bone mineral density in healthy, postmenopausal women Menopause 9 2002 343 353
17. B. Ettinger, A.R. Pressman Effect of age on reasons for initiation and discontinuation of hormone replacement therapy Menopause 6 1999 282 289
18. J.H. Pickar, I.-T. Yeh, J.E. Wheeler, M.F. Cunnane, L. Speroff Endometrial effects of lower doses of conjugated estrogens and medroxyprogesterone acetate Fertil Steril 76 2001 25 31
19. J. Brynhildsen, M. Hammar Low dose transdermal estradiol/norethisterone acetate treatment over 2 years does not cause endometrial proliferation in postmenopausal women Menopause 9 2002 137 144
20. B. Ettinger, J. Selby, J.T. Citron Cyclic hormone replacement therapy using quarterly progestin Obstet Gynecol 83 1994 693 700
21. B. Ettinger, A. Pressman, A. VanGessel Low-dosage esterified estrogen opposed by progestin at 6-month intervals Obstet Gynecol 98 2001 205 211
22. B. Ettinger, L. Bainton, D.H. Upmalis, J.T. Citron, A. VanGessel Comparison of endometrial growth produced by unopposed conjugated estrogens or by micronized estradiol in postmenopausal women Am J Obstet Gynecol 176 1997 112 117
23. The 2004 Gallup Study of Women's Experiences with Hormone Replacement Therapy. Princeton, NJ: Multi-sponsor Surveys, Inc. Catalog No. 257. Available at: http://www.multi-sponsorsurveys.com. Accessed February 17, 2005.